Bio-Rad Laboratories (FRA:BUWA) Total Noninterest Expense

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BUWA Bio-Rad Laboratories Inc FRA:BUWA
70 GF Score
Price €297.00
GF Value €273.61
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Bio-Rad Laboratories Total Noninterest Expense?

Total Noninterest Expense only applies to banks.

FRA:BUWA
70GF Score
Bio-Rad Laboratories Inc FRA:BUWA
Total Noninterest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bio-Rad Laboratories (FRA:BUWA) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be overvalued. The current stock price of €297.00 is trading 8.5% above its estimated GF Value™ of €273.61. GuruFocus considers Bio-Rad Laboratories to be Fairly Valued.

Key valuation signals for FRA:BUWA:

  • Total Noninterest Expense:
  • GF Value™: €273.61 vs. price of €297.00 (8.5% above fair value)
  • GF Score™: 70/100 with 7 warning signs

No single metric tells the full story. See the FRA:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bio-Rad Laboratories Business Description

Address 1000 Alfred Nobel Drive, Hercules, CA, USA, 94547
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
70GF Score

Get the complete analysis for FRA:BUWA

Total Noninterest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€297.00
Price
€273.61
GF Value